Physician profile
Ghulam M Khaleel
NPI 1669486007
$12,691.14
in general payments reported to CMS, 2019-2025
47 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,450 · 2020: $1,318 · 2021: $1,780 · 2022: $1,965 · 2023: $1,454 · 2024: $3,132 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,823 · Travel and Lodging: $1,353 · Education: $2.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,823.16 |
| Travel and Lodging | $1,353.11 |
| Education | $2.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,873.27 | 2019-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $1,337.28 | 2019-2025 | |
| Biogen, INC. | $1,045.45 | 2019-2025 | Vumerity, Skyclarys, Tysabri |
| Sk Life Science, INC. | $929.92 | 2020-2025 | Xcopri |
| Ucb, INC. | $787.58 | 2020-2025 | Briviact, Nayzilam |
| Supernus Pharmaceuticals, INC. | $679.44 | 2019-2022 | |
| Abbvie INC. | $609.21 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $502.14 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $481.47 | 2019-2023 | Rytary |
| Neurelis, INC. | $454.29 | 2020-2025 | Valtoco |
| Amgen INC. | $440.95 | 2019-2025 | Uplizna, Aimovig |
| Eisai INC. | $427.27 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $344.65 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $319.78 | 2019-2023 | Mavenclad |
| Neurocrine Biosciences, INC. | $200.25 | 2020-2025 | Ingrezza |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $199.22 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Mdd US Operations, LLC | $188.54 | 2022-2024 | Apokyn, Apokyn, Myobloc |
| Otsuka America Pharmaceutical, INC. | $182.97 | 2023-2025 | Rexulti |
| Tanabe Pharma America, INC. | $141.86 | 2020-2024 | |
| Genzyme Corporation | $125.74 | 2019-2022 | |
| Kyowa Kirin, INC. | $115.17 | 2020-2025 | Nourianz |
| Biohaven Pharmaceuticals, INC. | $111.84 | 2021 | |
| Banner Life Sciences, LLC | $89.41 | 2022-2023 | |
| Immedica Pharma US, INC. | $86.51 | 2024 | |
| Argenx US, INC. | $86.50 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $77.73 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Sumitomo Pharma America, INC. | $75.61 | 2023 | Aptiom |
| Nevro Corp. | $73.80 | 2023-2024 | Senza |
| Pfizer INC. | $73.12 | 2023-2024 | |
| Allergan, INC. | $69.10 | 2020 | |
| Lundbeck LLC | $58.53 | 2022-2025 | Vyepti, Rexulti |
| Inspire Medical Systems, INC. | $49.12 | 2024 | Inspire |
| Zyla Life Sciences, INC. | $47.93 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $45.25 | 2025 | Journavx |
| Catalyst Pharmaceuticals, INC. | $41.77 | 2022-2023 | Fycompa |
| Upsher-Smith Laboratories LLC | $39.42 | 2019 | |
| Merck Sharp & Dohme LLC | $36.37 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.89 | 2022 | |
| Scilex Pharmaceuticals INC. | $35.56 | 2025 | Elyxyb - Celecoxib |
| Acorda Therapeutics, INC | $33.66 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.81 | 2024 | Caplyta |
| Csl Behring | $29.73 | 2020-2021 | |
| Kedrion Biopharma, INC. | $20.87 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Brainsway USA INC | $19.80 | 2022 | |
| Currax Pharmaceuticals LLC | $15.35 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.04 | 2023 | Quviviq |
| Kinex Medical Company LLC | $4.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghulam Khaleel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.